Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.

Martin Gutierrez; Georgina V. Long; Claire Frances Friedman; Donald A. Richards; Bradley Corr; Bruno R. Bastos; Marc Isamu Uemura; Paul R. Conkling; Victor Moreno; William Jeffery Edenfield; Carlos Roberto Becerra; Sarina Anne Piha-Paul; Amy C. Peterson; Michelle Brown; Lee P. James; Ming Zheng; Jieying Jiang; Georgia Kollia; Ailsa Swijter; Paolo Antonio Ascierto

doi:10.1200/JCO.2020.38.15_SUPPL.3058

Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.

Martin Gutierrez, Georgina V. Long, Claire Frances Friedman, Donald A. Richards, Bradley Corr, Bruno R. Bastos, Marc Isamu Uemura, Paul R. Conkling, Victor Moreno, William Jeffery Edenfield, Carlos Roberto Becerra, Sarina Anne Piha-Paul, Amy C. Peterson, Michelle Brown, Lee P. James, Ming Zheng, Jieying Jiang, Georgia Kollia, Ailsa Swijter, Paolo Antonio Ascierto

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.3058
State	Published - 2020
Event	2020 ASCO Annual Meeting - Duration: Jan 1 2020 → …

Conference

Conference	2020 ASCO Annual Meeting
Period	1/1/20 → …

Disciplines

Oncology
Pathology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1200/JCO.2020.38.15_SUPPL.3058License: Unspecified

Cite this

Gutierrez, M., Long, G. V., Friedman, C. F., Richards, D. A., Corr, B., Bastos, B. R., Uemura, M. I., Conkling, P. R., Moreno, V., Edenfield, W. J., Becerra, C. R., Piha-Paul, S. A., Peterson, A. C., Brown, M., James, L. P., Zheng, M., Jiang, J., Kollia, G., Swijter, A., & Ascierto, P. A. (2020). Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.. 2020 ASCO Annual Meeting. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.3058

Gutierrez, M, Long, GV, Friedman, CF, Richards, DA, Corr, B, Bastos, BR, Uemura, MI, Conkling, PR, Moreno, V, Edenfield, WJ, Becerra, CR, Piha-Paul, SA, Peterson, AC, Brown, M, James, LP, Zheng, M, Jiang, J, Kollia, G, Swijter, A & Ascierto, PA 2020, 'Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.', 2020 ASCO Annual Meeting, 1/1/20. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.3058

@conference{325007ef4f6844dea09413a8b5911f61,

title = "Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.",

author = "Martin Gutierrez and Long, \{Georgina V.\} and Friedman, \{Claire Frances\} and Richards, \{Donald A.\} and Bradley Corr and Bastos, \{Bruno R.\} and Uemura, \{Marc Isamu\} and Conkling, \{Paul R.\} and Victor Moreno and Edenfield, \{William Jeffery\} and Becerra, \{Carlos Roberto\} and Piha-Paul, \{Sarina Anne\} and Peterson, \{Amy C.\} and Michelle Brown and James, \{Lee P.\} and Ming Zheng and Jieying Jiang and Georgia Kollia and Ailsa Swijter and Ascierto, \{Paolo Antonio\}",

note = "3058 Background: Blockade of the CTLA-4 pathway with ipilimumab (IPI) ± nivolumab (NIVO; anti-PD-1) is an effective treatment for a variety of cancers. To optimize the risk-benefit profile of CTLA-4-directed therapy, a Probody therapeutic technology platform (Pb-Tx, CytomX Therapeutics) was used to generate BMS-986249, a peptide-masked version of IPI that is unmasked by tumor-associated proteases.; 2020 ASCO Annual Meeting ; Conference date: 01-01-2020",

year = "2020",

doi = "10.1200/JCO.2020.38.15\_SUPPL.3058",

language = "American English",

}

TY - CONF

T1 - Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.

AU - Gutierrez, Martin

AU - Long, Georgina V.

AU - Friedman, Claire Frances

AU - Richards, Donald A.

AU - Corr, Bradley

AU - Bastos, Bruno R.

AU - Uemura, Marc Isamu

AU - Conkling, Paul R.

AU - Moreno, Victor

AU - Edenfield, William Jeffery

AU - Becerra, Carlos Roberto

AU - Piha-Paul, Sarina Anne

AU - Peterson, Amy C.

AU - Brown, Michelle

AU - James, Lee P.

AU - Zheng, Ming

AU - Jiang, Jieying

AU - Kollia, Georgia

AU - Swijter, Ailsa

AU - Ascierto, Paolo Antonio

N1 - 3058 Background: Blockade of the CTLA-4 pathway with ipilimumab (IPI) ± nivolumab (NIVO; anti-PD-1) is an effective treatment for a variety of cancers. To optimize the risk-benefit profile of CTLA-4-directed therapy, a Probody therapeutic technology platform (Pb-Tx, CytomX Therapeutics) was used to generate BMS-986249, a peptide-masked version of IPI that is unmasked by tumor-associated proteases.

PY - 2020

Y1 - 2020

UR - http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3058

U2 - 10.1200/JCO.2020.38.15_SUPPL.3058

DO - 10.1200/JCO.2020.38.15_SUPPL.3058

M3 - Presentation

T2 - 2020 ASCO Annual Meeting

Y2 - 1 January 2020

ER -

Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.

Conference

Disciplines

Access to Document

Other files and links

Cite this